Eli Lilly has launched weight-loss drug Mounjaro in India, priced at Rs 3,500 per injection for a 2.5mg dose. Will high costs ...

A Lilly statement said, "We will continue to take action to stop these illegal actors and urgently call on regulators and law ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better ...

Key Takeaways Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and ...

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...